Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol

Al-Laith, M.; Jasenecova, M.; Abraham, S.; Bosworth, A.; Bruce, I.N.; Buckley, C.D.; ... ; Cope, A.P. (2019)

Article / Letter to editor

• Rheumatoid arthritis
• At risk
• Pre-clinical phase
• Intervention
• Abatacept
• Double-blind
• Antibodies to citrullinated protein antigens
• Autoantibodies
• Placebo-controlled
• Randomised

• All authors: Al-Laith, M.; Jasenecova, M.; Abraham, S.; Bosworth, A.; Bruce, I.N.; Buckley, C.D.; Ciurtin, C.; D'Agostino, M.A.; Emery, P.; Gaston, H.; Isaacs, J.D.; Filer, A.; Fisher, B.A.; Huizinga, T.W.J.; Ho, P.; Jacklin, C.; Lempp, H.; McInnes, I.B.; Pratt, A.G.; Ostor, A.; Raza, K.; Taylor, P.C.; Schaardenburg, D. van; Shivapatham, D.; Wright, A.J.; Vasconcelos, J.C.; Kelly, J.; Murphy, C.; Prevost, A.T.; Cope, A.P.
• Date: 2019-07-15
• Journal: Trials
• Volume: 20
• DOI: doi:10.1186/s13063-019-3403-7